Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: The NICE ADHD health technology assessment: A review and critique. | Child and Adolescent Psychiatry and Mental Health BioMed Central Research Open Access The NICE ADHD health technology assessment A review and critique Michael Schlander1 2 3 Address 1Institute for Innovation Valuation in Health Care InnoValHC Rathausplatz 12-14 D-65760 Eschborn Germany 2Department of Public Health Social and Preventive Medicine Mannheim Medical Faculty University of Heidelberg Ludolf-Krehl-Strasse 7-11 D-68167 Mannheim Germany and 3University of Applied Economic Sciences Ludwigshafen Ernst-Boehe-Strasse 4 D-67059 Ludwigshafen Germany Email Michael Schlander- ms@ Published 15 January 2008 Received 23 July 2007 Child and Adolescent Psychiatry and Mental Health 2008 2 1 doi 1753-2000-2-1 Accepted 15 January 2008 This article is available from http content 2 1 1 2008 Schlander licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Health technology assessments HTAs by the National Institute for Health and Clinical Excellence NICE enjoy high levels of international attention. The present analysis addresses NICE s appraisal of methylphenidate atomoxetine and dexamphetamine for attention-deficit hyperactivity disorder ADHD in children and adolescents published in March 2006. Methods A qualitative study of NICE Technology Appraisal No. 98 was done focusing on the 600-page technology assessment report which aimed at evaluating ADHD treatment strategies by a clinical effectiveness review and an economic analysis using meta-analytical techniques and a cost-effectiveness model. Results The technology assessment was unable to differentiate between the various drugs in terms of efficacy and its economic model was ultimately driven by cost differences. While the .
